EpiConcept, Paris, France.
Euro Surveill. 2013 Feb 14;18(7):3.
We conducted a test-negative case-control study based in five European sentinel surveillance networks. The early 2012/13 adjusted influenza vaccine effectiveness was 78.2% (95% CI: 18.0 to 94.2) against influenza B, 62.1% (95% CI: -22.9 to 88.3%) against A(H1) pdm09, 41.9 (95% CI: -67.1 to 79.8) against A(H3N2) and 50.4% (95% CI: -20.7 to 79.6) against all influenza types in the target groups for vaccination. Efforts to improve influenza vaccines should continue to better protect those at risk of severe illness or complications.
我们在五个欧洲监测哨点网络中开展了一项病例对照研究。2012 年/2013 年年初调整后的流感疫苗针对乙型流感的有效率为 78.2%(95%CI:18.0 至 94.2),针对 A(H1)pdm09 的有效率为 62.1%(95%CI:-22.9 至 88.3%),针对 A(H3N2)的有效率为 41.9%(95%CI:-67.1 至 79.8),针对所有流感类型的有效率为 50.4%(95%CI:-20.7 至 79.6),这些有效率都是在目标接种人群中观察到的。为了更好地保护那些有罹患重病或并发症风险的人群,应继续努力改进流感疫苗。